It has been reported that hypereosinophilic syndrome may be induced by antituberculosis drugs. We herein report the case of a 43-year-old man who had been on antituberculosis drugs for two months to treat tuberculous meningitis. During therapy, he suffered from drug rash with eosinophilia and systemic symptoms (DRESS) presenting as acute eosinophilic myocarditis, as confirmed on a histopatholog...

A 61-year-old man was admitted a confirmed COVID-19 with comorbid pulmonary tuberculosis and type 2 diabetes mellitus. The patient given favipiravir therapy, category 1 of antituberculosis drug, insulin therapy. responded well to therapy improved clinical laboratory indicators.
 Key words: COVID-19, tuberculosis, mellitus

In this study, eight new ethyl {2-[3,4-diaryl-3H-thiazol-2ylidenamino]thiazol-4-yl}acetate were synthesized by reacting ethyl [2-(3-aryl(thiouredio)thiazol-4-yl]acetate and phenacyl bromides in ethanol. The solid was filtered and recrystallized from ethanol. The chemical structures of the synthesized compounds were proven by elemental analysis, IR, 1H-NMR and MS spectral data. The compounds wer...

In the critical search for new antituberculosis lead compounds, bryophytes represent a largely untapped resource of chemically diverse structures. From the liverwort Jungermannia exsertifolia subsp. cordifolia, 11 new trachylobane diterpene derivatives, as well as three known compounds, were isolated. Their structures were elucidated by spectroscopic means, and full (1)H NMR spin analysis of on...

The potential for drug-drug interactions mediated by the inhibition of cytochrome P-450 (CYP) were concerned during antituberculosis therapy. However, the information regarding human CYP inhibition by antituberculosis drugs is limited to isoniazid. In the current study, we examined the inhibitory effects of pyrazinamide and ethionamide, both of which are chemically related to isoniazid, on the ...

Antituberculosis drug-induced liver injury (ATDILI) is the most prevalent hepatotoxicity in many countries. All of the three first-line antituberculosis drugs, isoniazid, rifampicin, and pyrazinamide, may induce hepatic damage, especially isoniazid. The major drug-metabolizing enzyme of isoniazid is N-acetyltransferase (NAT). Other possible enzymes are CYP2E1, glutathione S-transferase (GST) an...

Tuberculosis is the seventh leading cause of morbidity and mortality in the world, with eight million cases per year. Animal and human studies demonstrate an enrichment of CD4 cells at sites of disease, with a more favorable clinical course when there is a Th1 response with the presence of gamma interferon (IFN-gamma). We previously treated patients who had multidrug-resistant tuberculosis with...